Topic: venture capital (VC)
Truvian Sciences raised $27.1 million to fuel the development of its benchtop blood tester, bringing the company’s total funding to $46.3 million.
Werewolf is launching with $56 million and an approach that can cut through the toxic effects that have limited certain cancer-killing agents.
The partners will use $25 million in Novo Ventures’ money to fund drug discovery projects led by researchers at the Broad.
The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year.
Atomwise and Velocity Pharmaceutical Development co-founded a company to carry AI-derived drugs through preclinical testing and into takeout deals.
Sera Prognostics has raised $36 million in funding to help commercialize its blood test for assessing the risk of premature births.
Avidity Biosciences is on a roll—after inking an R&D deal with Eli Lilly and hiring a new CEO, the company is reeling in $100 million.
Armed with $44 million, Arkuda Therapeutics is going after a protein that plays a role in neuronal health and lysosomal function to treat dementia.
eGenesis has raised $100 million for its xenotransplantation efforts, led by the venture capital arm of dialysis provider Fresenius Medical Care.
The series B funding will ramp up PathAI's R&D into new digital tools and medical devices for the diagnosis of diseases like cancer.